Terms: = Leukemia AND SETD2, ENSG00000181555, 29072 AND Treatment
15 results:
1. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
2. Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia.
Vráblová L; Divoký V; Kořalková P; Poláková KM; Kriegová E; Janská R; Grohmann J; Holzerová M; Papajík T; Faber E
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768374
[TBL] [Abstract] [Full Text] [Related]
3. setd2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients.
Liu H
Hematology; 2023 Dec; 28(1):2161194. PubMed ID: 36607144
[TBL] [Abstract] [Full Text] [Related]
4. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
Zhou B; Chu X; Tian H; Liu T; Liu H; Gao W; Chen S; Hu S; Wu D; Xu Y
Am J Hematol; 2021 Nov; 96(11):1461-1471. PubMed ID: 34406703
[TBL] [Abstract] [Full Text] [Related]
5. Intra-heterogeneity in transcription and chemoresistant property of leukemia-initiating cells in murine setd2
Song J; Du L; Liu P; Wang F; Zhang B; Xie Y; Lu J; Jin Y; Zhou Y; Lv G; Zhang J; Chen S; Chen Z; Sun X; Zhang Y; Huang Q
Cancer Commun (Lond); 2021 Sep; 41(9):867-888. PubMed ID: 34196511
[TBL] [Abstract] [Full Text] [Related]
6. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
Chapiro E; Pramil E; Diop M; Roos-Weil D; Dillard C; Gabillaud C; Maloum K; Settegrana C; Baseggio L; Lesesve JF; Yon M; Jondreville L; Lesty C; Davi F; Le Garff-Tavernier M; Droin N; Dessen P; Algrin C; Leblond V; Gabarre J; Bouzy S; Eclache V; Gaillard B; Callet-Bauchu E; Muller M; Lefebvre C; Nadal N; Ittel A; Struski S; Collonge-Rame MA; Quilichini B; Fert-Ferrer S; Auger N; Radford-Weiss I; Wagner L; Scheinost S; Zenz T; Susin SA; Bernard OA; Nguyen-Khac F; ;
Blood; 2019 Nov; 134(21):1821-1831. PubMed ID: 31527074
[TBL] [Abstract] [Full Text] [Related]
7. Downregulation of the histone methyltransferase setd2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract] [Full Text] [Related]
8. setd2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
Dong Y; Zhao X; Feng X; Zhou Y; Yan X; Zhang Y; Bu J; Zhan D; Hayashi Y; Zhang Y; Xu Z; Huang R; Wang J; Zhao T; Xiao Z; Ju Z; Andreassen PR; Wang QF; Chen W; Huang G
Leukemia; 2019 Nov; 33(11):2585-2598. PubMed ID: 30967619
[TBL] [Abstract] [Full Text] [Related]
9. [Precision genomic and translational medicine for acute myeloid leukemia].
Yu XX; Chen AL; Li YY; Liu D; Wang QF
Yi Chuan; 2018 Nov; 40(11):988-997. PubMed ID: 30465531
[TBL] [Abstract] [Full Text] [Related]
10.
Mar BG; Chu SH; Kahn JD; Krivtsov AV; Koche R; Castellano CA; Kotlier JL; Zon RL; McConkey ME; Chabon J; Chappell R; Grauman PV; Hsieh JJ; Armstrong SA; Ebert BL
Blood; 2017 Dec; 130(24):2631-2641. PubMed ID: 29018079
[TBL] [Abstract] [Full Text] [Related]
11. setd2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Martinelli G; Mancini M; De Benedittis C; Rondoni M; Papayannidis C; Manfrini M; Meggendorfer M; Calogero R; Guadagnuolo V; Fontana MC; Bavaro L; Padella A; Zago E; Pagano L; Zanotti R; Scaffidi L; Specchia G; Albano F; Merante S; Elena C; Savini P; Gangemi D; Tosi P; Ciceri F; Poletti G; Riccioni L; Morigi F; Delledonne M; Haferlach T; Cavo M; Valent P; Soverini S
Leukemia; 2018 Jan; 32(1):139-148. PubMed ID: 28663576
[TBL] [Abstract] [Full Text] [Related]
12. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing.
Masetti R; Castelli I; Astolfi A; Bertuccio SN; Indio V; Togni M; Belotti T; Serravalle S; Tarantino G; Zecca M; Pigazzi M; Basso G; Pession A; Locatelli F
Oncotarget; 2016 Aug; 7(35):56746-56757. PubMed ID: 27462774
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.
Griffith M; Griffith OL; Krysiak K; Skidmore ZL; Christopher MJ; Klco JM; Ramu A; Lamprecht TL; Wagner AH; Campbell KM; Lesurf R; Hundal J; Zhang J; Spies NC; Ainscough BJ; Larson DE; Heath SE; Fronick C; O'Laughlin S; Fulton RS; Magrini V; McGrath S; Smith SM; Miller CA; Maher CA; Payton JE; Walker JR; Eldred JM; Walter MJ; Link DC; Graubert TA; Westervelt P; Kulkarni S; DiPersio JF; Mardis ER; Wilson RK; Ley TJ
Exp Hematol; 2016 Jul; 44(7):603-13. PubMed ID: 27181063
[TBL] [Abstract] [Full Text] [Related]
14. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
[TBL] [Abstract] [Full Text] [Related]
15. Mutations in epigenetic regulators including setd2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
[TBL] [Abstract] [Full Text] [Related]
